Abstract
BackgroundIxekizumab (IXE), an anti-interleukin-17A monoclonal antibody, was shown to be superior to placebo (PBO) in clinical responses and inhibiting the progression of structural joint damage in patients (pts) with psoriatic...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have